Allergan Plc
- All
- News
-
Cipla Divests 16.7% Stake In Chase Pharma To Allergan
Delaware-based Chase Pharmaceuticals Corporation, in which the company's UK arm Cipla (EU) Ltd has 16.7 per cent stake, has been acquired by a subsidiary of Allergan plc, Cipla said in a statement.
-
Teva To Sell Allergan's Generics Business In UK, Ireland To Intas Pharmaceuticals
Greenhill & Co is Teva's financial adviser, while Rothschild & Co is advising Intas Pharmaceuticals.
-
Dr Reddy's Completes Acquisition Of Products From Teva Pharma
Dr Reddy's Laboratories on Wednesday said it has successfully completed the $350-million (around Rs 2,300 crore) acquisition of eight abbreviated new drug applications (ANDAs) in the US from Teva Pharmaceutical Industries and an affiliate of Allergan plc.
-
Dr Reddy's Laboratories To Buy 8 Drugs From Teva Pharmaceutical, Shares Gain
The combined sales of the branded versions of the products in the US is around $3.5 billion, Dr Reddy's added.
-
Pfizer To Buy Anacor In $5.2 Billion Deal For Access To Eczema Gel
Pfizer Inc will buy Anacor Pharmaceuticals Inc in a deal valued at $5.2 billion, net of cash, for access to Anacor's non-steroidal topical gel to treat eczema.
-
Pfizer, Allergan Scrap $160-Billion 'Inversion' Deal
US drug maker Pfizer Inc and Ireland-based Allergan Plc formally announced the scrapping of their $160 billion merger on Wednesday, in a big win for President Barack Obama who has been pushing to curb tax-slashing "inversion" deals.
-
US Politicians Slam Tax-Avoiding Pfizer-Allergan Deal
More than 50 similar deals have been done over three decades by well-known companies such as Medtronic Plc, Fruit of the Loom and Ingersoll-Rand Plc. Congressional researchers have estimated inversions, left unchecked, will cost the US Treasury nearly $20 billion in the next 10 years.
-
US Politicians Slam Tax-Avoiding Pfizer-Allergan Deal
US politicians condemned Pfizer Inc's deal with Allergan Plc as a tax dodge on Monday, bringing another round of hand-wringing in Washington over the corporate tax code, though legislative action before 2017 is unlikely.
-
Pfizer to Buy Allergan in Record $160 Billion Deal
Pfizer Inc on Monday said it would buy Botox maker Allergan Plc in a record-breaking deal worth $160 billion (Rs 10.56 lakh crore at $1 = Rs 66) to cut its US tax bill by moving its headquarters to Ireland.
-
Pfizer, Allergan Combining in $160 Billion Deal to Become Largest Drugmaker
Pfizer and Allergan will join in a $160 billion deal to create the world's largest drugmaker.
-
Pfizer Set to Buy Allergan in Largest Deal Ever in Healthcare Sector: Report
Pfizer Inc was due to secure formal board approval on Sunday for its acquisition of Botox maker Allergan Plc for more than $150 billion, creating the world's biggest drug maker, according to people familiar with the matter.
-
Pfizer-Allergan Talks Accelerate Amid New Inversion Clamp-Down
Pfizer Inc's talks to acquire Allergan Plc in a $150 billion deal that would see the U.S. drug giant redomicile in Ireland accelerated on Wednesday, as the U.S. Treasury prepared to clamp down further on such tax inversions.
-
Pfizer in Talks With Allergan to Forge $330-Billion Drug Giant: Report
Pharmaceutical giant Pfizer Inc has held early talks with Botox-maker Allergan Plc to discuss what could be the biggest takeover deal this year, the Wall Street Journal and Financial Times reported.
-
Teva To Buy Allergan Generic Drug Business for $40.5 Bn
Allergan's generic business is generally seen as a better fit than Teva's previous target Mylan because it will improve Teva's distribution channels and because Allergan is strong in so-called biosimilar drugs.
-
Cipla Divests 16.7% Stake In Chase Pharma To Allergan
Delaware-based Chase Pharmaceuticals Corporation, in which the company's UK arm Cipla (EU) Ltd has 16.7 per cent stake, has been acquired by a subsidiary of Allergan plc, Cipla said in a statement.
-
Teva To Sell Allergan's Generics Business In UK, Ireland To Intas Pharmaceuticals
Greenhill & Co is Teva's financial adviser, while Rothschild & Co is advising Intas Pharmaceuticals.
-
Dr Reddy's Completes Acquisition Of Products From Teva Pharma
Dr Reddy's Laboratories on Wednesday said it has successfully completed the $350-million (around Rs 2,300 crore) acquisition of eight abbreviated new drug applications (ANDAs) in the US from Teva Pharmaceutical Industries and an affiliate of Allergan plc.
-
Dr Reddy's Laboratories To Buy 8 Drugs From Teva Pharmaceutical, Shares Gain
The combined sales of the branded versions of the products in the US is around $3.5 billion, Dr Reddy's added.
-
Pfizer To Buy Anacor In $5.2 Billion Deal For Access To Eczema Gel
Pfizer Inc will buy Anacor Pharmaceuticals Inc in a deal valued at $5.2 billion, net of cash, for access to Anacor's non-steroidal topical gel to treat eczema.
-
Pfizer, Allergan Scrap $160-Billion 'Inversion' Deal
US drug maker Pfizer Inc and Ireland-based Allergan Plc formally announced the scrapping of their $160 billion merger on Wednesday, in a big win for President Barack Obama who has been pushing to curb tax-slashing "inversion" deals.
-
US Politicians Slam Tax-Avoiding Pfizer-Allergan Deal
More than 50 similar deals have been done over three decades by well-known companies such as Medtronic Plc, Fruit of the Loom and Ingersoll-Rand Plc. Congressional researchers have estimated inversions, left unchecked, will cost the US Treasury nearly $20 billion in the next 10 years.
-
US Politicians Slam Tax-Avoiding Pfizer-Allergan Deal
US politicians condemned Pfizer Inc's deal with Allergan Plc as a tax dodge on Monday, bringing another round of hand-wringing in Washington over the corporate tax code, though legislative action before 2017 is unlikely.
-
Pfizer to Buy Allergan in Record $160 Billion Deal
Pfizer Inc on Monday said it would buy Botox maker Allergan Plc in a record-breaking deal worth $160 billion (Rs 10.56 lakh crore at $1 = Rs 66) to cut its US tax bill by moving its headquarters to Ireland.
-
Pfizer, Allergan Combining in $160 Billion Deal to Become Largest Drugmaker
Pfizer and Allergan will join in a $160 billion deal to create the world's largest drugmaker.
-
Pfizer Set to Buy Allergan in Largest Deal Ever in Healthcare Sector: Report
Pfizer Inc was due to secure formal board approval on Sunday for its acquisition of Botox maker Allergan Plc for more than $150 billion, creating the world's biggest drug maker, according to people familiar with the matter.
-
Pfizer-Allergan Talks Accelerate Amid New Inversion Clamp-Down
Pfizer Inc's talks to acquire Allergan Plc in a $150 billion deal that would see the U.S. drug giant redomicile in Ireland accelerated on Wednesday, as the U.S. Treasury prepared to clamp down further on such tax inversions.
-
Pfizer in Talks With Allergan to Forge $330-Billion Drug Giant: Report
Pharmaceutical giant Pfizer Inc has held early talks with Botox-maker Allergan Plc to discuss what could be the biggest takeover deal this year, the Wall Street Journal and Financial Times reported.
-
Teva To Buy Allergan Generic Drug Business for $40.5 Bn
Allergan's generic business is generally seen as a better fit than Teva's previous target Mylan because it will improve Teva's distribution channels and because Allergan is strong in so-called biosimilar drugs.
